Capvaxive uniquely adds eight adult-predominant invasive serotypes absent from other approved pneumococcal vaccines, ...

Additive manufacturing allows pharma and biotech companies to take advantage of 3D printing technology to produce medications ...

Kardigan raised $400M gross by selling 25M shares at $16, with a 3.75M-share greenshoe, and shares jumped up to 31% on debut. Three late-stage programs target high-unmet cardiovascular niches: ...

A rare tumor launch using claims plus behavioral triggers and KOL-balanced content exceeded forecasts, attributing 60% of new ...

As Connecticut moves to rein in private equity's playbook in hospital deals, pharma and life sciences leaders face a parallel ...

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...

FDA approved Utebzi, an oral carbapenem antibiotic developed by GSK in partnership with Spero Therapeutics, for the treatment of complicated urinary tract infections (cUTI) including pyelonephritis in ...

Kardigan’s offering proposes 23.3 million shares at $14–$16, targeting ~$350 million gross proceeds and an implied ~$1.3 ...

RayThera contributes multiple undisclosed-mechanism small-molecule immunology candidates positioned for broad applicability across immune-mediated indications, expanding modality diversity beyond ...

Silvia Taylor of Novavax details how the company leverages its expertise in vaccine development to build partnerships across ...

Brian Hilberdink, president of U.S. Human Pharma, Boehringer Ingelheim, explains why shifting the conversation from simple ...

Bexobrutideg leverages targeted protein degradation to eliminate BTK, potentially overcoming resistance mutations and ...